Getting medicines to those who need them most
We recognize that the patients and families who battle life-threatening diseases anxiously await more effective medicines with each passing day. Knowing this drives us to work harder, to deliver transformative treatments more swiftly.
We also seek to ensure any medicine we develop is safe and effective and follows the rigorous guidelines established by regulatory agencies.
We strive to balance these two complementary and vital goals in all that we do.
To learn more about our clinical trials, visit blueprintclinicaltrials.com or contact us in the U.S. at medinfo@blueprintmedicines.com or 1-888-BLU-PRNT (1-888-258-7768), and in Europe at medinfoeurope@blueprintmedicines.com or +31 85 064 4001.Our clinical trials
Systemic mastocytosis (SM)
A clinical trial for people with advanced systemic mastocytosis
Trial Phase
Target Population
Aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia
Study Status
Active, fully enrolled
ClinicalTrials.gov
Study Number
NCT03580655
A clinical trial for people with indolent systemic mastocytosis
Trial Phase
Target Population
Indolent SM
Study Status
Active, recruiting
ClinicalTrials.gov
Study Number
NCT03731260
RET-altered cancers
A clinical trial for people with RET-altered cancers
Trial Phase
Target Population
RET-altered non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) or other solid tumors with a RET fusion or mutation
Study Status
Active, recruiting
ClinicalTrials.gov
Study Number
NCT03037385
A clinical trial for people with RET fusion-positive, metastatic non-small cell lung cancer (NSCLC)
Trial Phase
Target Population
First-line RET fusion-positive, metastatic NSCLC
Study Status
Active, recruiting
ClinicalTrials.gov
Study Number
NCT04222972
Hepatocellular carcinoma (HCC)
Trial Phase
Target Population
Locally advanced or metastatic HCC; conducted in China
Study Status
Active, recruiting
ClinicalTrials.gov
Study Number
NCT04194801
Learn more: clinicaltrials.gov/ct2/show/NCT04194801
Pre-approval access
An expanded access program (NCT04714086) is open in the United States for patients with advanced SM or smoldering SM. For additional information, visit clinicaltrials.gov or contact us at medinfo@blueprintmedicines.com.